Garcia VC, Mansfield C, Leach C, Pierce A, Smith JC, Afonso M. Patient and caregiver preferences for hemophilia treatments: a discrete-choice experiment. Haemophilia. 2024 Mar;30(2):375-87. doi: 10.1111/hae.14928
Jeuland M, McClatchey M, Patil SR, Pattanayak SK, Poulos CM, Chen Yang J. Do decentralized community treatment plants provide clean water? Evidence from rural Andhra Pradesh, India. Land Econ. 2021 May;97(2).
Ayad M, Karanth S, Narat M, Luther K, Patel B. Outcomes of creating an automated repeat lactate rule in sepsis patients with lactate levels ≥2. Poster presented at the 2019 Institute for Healthcare Improvement (IHI) Scientific Symposium; December 2019. Orlando, FL. [abstract] BMJ Open Qual. 2019; 8(Suppl 2):A39. doi: 10.1136/bmjoq-2019-ihi.23
Liu X, Sarr M, Swanson T. Resistance to the regulation of common water resources in rural Tunisia. Land Econ. 2015 Aug;91:435-59. doi: 10.3368/le.91.3.435
Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015 May;21(3):310-9. doi: 10.1111/hae.12621
Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry. Haemophilia. 2015 Mar;21(2):e122-4. doi: 10.1111/hae.12590
DiBenedetti DB, Coles TM, Sharma T, Pericleous L, Kulkarni R. Assessing patients' and caregivers' perspectives on stability of factor VIII products for haemophilia A: a web-based study in the United States and Canada. Haemophilia. 2014 Jul;20(4):e296-303. doi: 10.1111/hae.12459
Glück S, Russell C, O'Shaughnessy J, McKenna EF, Hu S, Odom D, Blum JL. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast. 2013 Dec;22(6):1087-93. doi: 10.1016/j.breast.2013.08.016.
Brown TM, Pashos CL, Joshi AV, Lee WC. The perspective of patients with haemophilia with inhibitors and their care givers: preferences for treatment characteristics. Haemophilia. 2011 May 1;17(3):476-82.
Brown TM, Lee WC, Joshi AV, Pashos CL. Health-related quality of life and productivity impact in haemophilia patients with inhibitors. Haemophilia. 2009 Jul 1;15(4):911-7.
Von Scheele BG, Martin RD, Gilsenan AW, Ceberg J, Andrews EB, Masica D, Alvegård T. The European postmarketing adult osteosarcoma surveillance study characteristics of patients: a preliminary report. Acta Orthop. 2009;80:67-74.
Lee WC, Joshi AV, Woolford S, Sumner M, Brown TM, Hadker N, Pashos CL. Physicians' preferences towards coagulation factor concentrates in the treatment of haemophilia with inhibitors: a discrete choice experiment. Haemophilia. 2008 May 1;3(14):454-65.
Mansfield CA, Phaneuf D, Johnson FR, Yang J, Beach RH. Preferences for public lands management under competing uses: the case of Yellowstone National Park. Land Econ. 2008 May 1;84(2):282-305.
Mansfield CA, Van Houtven GL, Huber J. Compensating for public harms: why public goods are preferred to money. Land Econ. 2002;78(3):368-89.